Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

(2011) Leisl M. Packer et al.   CANCER CELL

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

DDR1 Receptor Tyrosine Kinase Promotes Prosurvival Pathway through Notch1 Activation

(2011) Hyung-Gu Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

A MEK-independent role for CRAF in mitosis and tumor progression

(2011) Ainhoa Mielgo et al.   NATURE MEDICINE

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

BRAF, a target in melanoma

(2010) Keith T. Flaherty et al.   CANCER

BRAF Inactivation Drives Aneuploidy by Deregulating CRAF

(2010) T. Kamata et al.   CANCER RESEARCH

Targets of Raf in tumorigenesis

(2010) T. S. Niault et al.   CARCINOGENESIS

The Brothers RAF

(2010) Lawrence N. Kwong et al.   CELL

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer

(2010) B. Sen et al.   CLINICAL CANCER RESEARCH

Acute Insulin Signaling in Pancreatic Beta-Cells Is Mediated by Multiple Raf-1 Dependent Pathways

(2010) Emilyn U. Alejandro et al.   ENDOCRINOLOGY

The essence of senescence

(2010) T. Kuilman et al.   GENES & DEVELOPMENT

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Faye M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

(2010) Jiannong Li et al.   Nature Chemical Biology

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier

(2010) O. E. Sturm et al.   Science Signaling

Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding

(2009) B. Sen et al.   CANCER RESEARCH

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

(2009) Martin L. Sos et al.   JOURNAL OF CLINICAL INVESTIGATION

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

(2008) K S M Smalley et al.   ONCOGENE